FIRST APTAMER FOR RAPID D-DIMER CLINICAL DIAGNOSTICS APPLICATION
Ayass Bioscience, LLC developed the FIRST APTAMER for the D-Dimer Test to Rule Out Suspected Pulmonary Embolism (PE), Deep Venous Thrombosis (DVT), Stroke, Disseminated Intravascular Coagulation (DIC)!
Aptamers are molecules with extraordinary potential, but their use in clinical practice is sadly limited for now, despite major success of aptamer technology in the last 10 years.
Aptamers are more stable, faster, and inexpensive to produce, and possess a longer shelf life compared to antibodies.
Ayass Bioscience, LLC developed Aptamer for the D-Dimer series of Fibrin Degradation Products, a critical blood clot level index. D-Dimer levels are critical when deep venous thrombosis (DVT), pulmonary embolism (PE), or disseminated intravascular coagulation (DIC) are suspected. Timely decisions regarding surgical operations or administration of medications in these life-threatening conditions warrant the quantitation of D-dimer in patient blood samples as soon as possible.
Instead of using antibodies to detect D-Dimer in blood samples, the Aptamer discovered by Ayass BioScience, LLC is able to quantify the protein in blood samples. It is shown to be useful in homogeneous assays such as turbidimetry (comparable to clinically approved laboratory turbidimetric immunoassay) and in manual point-of-care agglutination tests.
Ayass Bioscience, LLC Aptamer discovery would not only lower the cost of D-Dimer testing but introduce longer-lasting test kits for laboratories and point-of-care testing for medical care providers.